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Antimicrobial resistance (AMR) is an important public health 
concern shared by developed and developing countries. In 
developing countries the burden of infectious diseases is greater and 
exacerbated by limited access to, and availability and affordability of, 
antimicrobials required to treat infections caused by AMR organisms. 
With drugs not listed on the essential drugs list (EDL), problems of 
increased morbidity, costs of extended hospitalisation and mortality 
are extremely serious. The problem of susceptibility to and spread of 
infections caused by multidrug-resistant (MDR) infectious agents is 
fuelled by factors such as limited access to clean water and sanitation 
to ensure personal hygiene, malnutrition, and the HIV/TB epidemic. 
AMR is a consequence of complex interactions of many 
factors, including inappropriate use (clinical indication, choice, 
administration and dosing) and poor quality of antimicrobials, 
inadequate infection prevention and control, empirical treatment 
prescribed because of inadequate laboratory support, problems with 
the supply chain, increased mobility of people as a result of ease of 
travel and escape from conflict zones, patient non-compliance in 
taking antimicrobials, and the use of antimicrobials in agricultural 
and veterinarian animal settings. In contrast to most developed 
countries, there are scant data on the extent of the problem and 
trends of AMR in developing countries, including South Africa. 
In South Africa, considerable AMR information can be found, 
or mined, from South African experts in the field and from 
public and private health sector data sources. ‘Classic’ community-
acquired infections such as sexually transmitted infections (STIs), 
opportunistic HIV/AIDS-related infections (e.g. cryptococcosis), 
specific enteric infections, and those caused by respiratory and 
meningeal pathogens (with particular, but not exclusive, focus on 
pneumococcal disease) have been researched in depth. Considerable 
information is available on the AMR challenges posed by some 
of these infections. Health care-associated infections, particularly 
Klebsiella pneumoniae and Staphylococcus aureus from bloodstream 
isolates, are being monitored for their AMR profiles and trends.
National AMR surveillance activities in South Africa have focused 
predominantly on data available from the National Antibiotic 
Surveillance Forum (NSAF), superseded by the current South African 
Society for Clinical Microbiology (SASCM), in the public health care 
sector. The NSAF (SASCM) reports data from eight microbiology 
laboratories affiliated to academic centres nationwide. Although this 
approach provides useful data, it has several limitations, e.g. data 
are only collected from large academic centres. Since this does not 
profile AMR in the general population attending primary, secondary 
and non-academic tertiary health care facilities, it precludes the 
possibility of assessing the true extent of the problem of AMR 
countrywide. The private sector carries out surveillance of AMR in 
pathogens isolated from various sources. Access to these data, and 
their limitations, are highlighted in part V (Surveillance activities) of 
this AMR situational analysis issue of SAMJ.
No discussion on AMR is complete without considering the impact 
of antimicrobial use in the veterinary sector. Although the impact 
on the development and spread of resistance from use in animals is 
debated globally, it is generally accepted that it is prudent to reduce 
unnecessary use. Valuable work done in this regard is discussed in part 
VI (Antibiotic management and resistance in livestock production).
In order to slow the spread of AMR among our population, 
it is clear that interventions such as immunisation and infection 
prevention and control programmes should be given high priority 
at national, provincial and local levels. Limiting the unnecessary use 
of antimicrobials and introducing systems of checks and balances to 
monitor misuse or overuse of antimicrobials are crucial to limit the 
problem of AMR. In addition to those of doctors and nurses, the 
roles of the infection prevention control practitioner and the clinical 
pharmacist must be enhanced to assist prevention of transmission 
of MDR pathogens and to curb inappropriate/incorrect use of 
antimicrobials.
Ultimately, South Africa’s contribution in investigating strategies 
and solutions to curb AMR does not end at national level. AMR is of 
global concern and some of the issues and solutions that we discover 
will undoubtedly be of interest and relevance in other countries. Thus 
we embrace our role as a founding country in an active and ongoing 
collaboration with the Global Antibiotic Resistance Partnership 
(GARP), whose mission, vision and proposed phases of work with 
regard to AMR are described in part I of this issue.
Finally, this is the first document to be published in South Africa 
that attempts to bring together all the initiatives, research and 
proposed future directions for dealing with AMR in our country. I 
thank all the contributing authors for the outstanding work that they 
have done, and will continue to pursue.
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